Showing results (1401-1410 of 1,434) with videos related to

Sort By:
Pageof 144
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Surgical Endoscopy|March 18, 2020
A large multicenter cohort on the use of full-thickness resection device for difficult colonic lesionsY Ichkhanian, K Vosoughi, D L Diehl, et al.
Nature Communications|May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 5, 2019
Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen Hearing Loss Expert PanelJun Shen, Andrea M Oza, Ignacio Del Castillo, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 23, 2025
ClinGen recuration of hearing loss-associated genes demonstrates significant changes in gene-disease validity over timeKezang C Tshering, Marina T DiStefano, Andrea M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona MeetingJalid Sehouli, Jolijn Boer, Alison H Brand, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2025
Management of the Disconnected Pancreatic Duct in Pancreatic NecrosisC Mel Wilcox, Ji Young Bang, Akwi Asombang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 4, 2024
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona MeetingJalid Sehouli, Jolijn Boer, Alison H Brand, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)T Shirakawa, M Shimokawa, T Otsuka, et al.
Journal of the American Academy of Dermatology|April 29, 2022
Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort studyN Ezeh, K Ardalan, K A Buhr, et al.
Pageof 144